Introduction {#tca12397-sec-0005}
============

Non‐small‐cell lung cancer (NSCLC), accounts for approximately 85% of primary lung cancers and remains the leading cause of cancer‐related death worldwide. Despite the encouraging improvement of treatment methods over the last decades, the five‐year survival rate is still low, which is mainly attributed to the large proportion of advanced cases at the time of diagnosis.[1](#tca12397-bib-0001){ref-type="ref"} Combination therapy based on platinum agents has been the most common form of treatment for advanced NSCLC, regardless of various therapy responses between patients.[2](#tca12397-bib-0002){ref-type="ref"} However, the major problem is the optimization of treatment options, which could help clinicians determine which patients will benefit from which therapy.

The *P73* gene, a structural and functional homolog of the *p53* gene, plays a crucial role in the presence of DNA damage induced by platinum‐based chemotherapy.[3](#tca12397-bib-0003){ref-type="ref"} The *p73* G4C14‐to‐A4T14 polymorphism consists of two single nucleotide polymorphisms (SNPs, rs2273953 and rs1801173), which are in complete linkage disequilibrium, located at positions 4 (G→A) and 14 (C→T) in the 5′ untranslated region (UTR) of exon 2, just upstream of the initiating AUG of the *p73* gene. It has been shown that the GC to AT change may form a stem‐loop structure and possibly affect the translation efficiency of *p73*.[4](#tca12397-bib-0004){ref-type="ref"} An increasing number of studies have investigated the relationship between the *p73* G4C14‐to‐A4T14 polymorphism and the susceptibility of various cancers, including lung, breast, esophageal, prostate, cervical, and gastric carcinoma in different ethnic populations.[5](#tca12397-bib-0005){ref-type="ref"}, [6](#tca12397-bib-0006){ref-type="ref"}, [7](#tca12397-bib-0007){ref-type="ref"}, [8](#tca12397-bib-0008){ref-type="ref"}, [9](#tca12397-bib-0009){ref-type="ref"}, [10](#tca12397-bib-0010){ref-type="ref"} In addition, evidence has also indicated that the expression level of the *p73* gene is a non‐ignorable factor of chemosensitivity in human tumors.[11](#tca12397-bib-0011){ref-type="ref"}

However, in spite of the well‐known impact of the *p73* G4C14‐to‐A4T14 polymorphism on cancer development, its potential role in chemotherapeutic response and prognosis of NSCLC has not been fully investigated. To further test the association, we performed a two‐stage association analysis for this validated polymorphism by conducting a discovery cohort with 642 advanced NSCLC patients who received platinum‐based chemotherapy followed by further replication in an independent replication cohort with 330 patients in a Chinese population.

Methods {#tca12397-sec-0006}
=======

Study population and follow‐up {#tca12397-sec-0007}
------------------------------

The discovery set included 642 cases with confirmed late‐stage (III--IV) NSCLC who had received platinum‐based chemotherapy between March 2005 and January 2010 in the oncological departments of Shanghai Zhongshan Hospital, Shanghai Chest Hospital, and Shanghai Changhai Hospital. Positive hits from the discovery set were validated in patients with advanced NSCLC from an independent replication cohort. This dataset included 330 advanced NSCLC cases from Shanghai Pulmonary Hospital between June 2010 and May 2013. Blood samples from all subjects were collected at the time of diagnosis, prior to chemotherapy treatment. All subjects provided written informed consent and the medical ethics committee of each participating institution approved the study.

Follow‐up was performed every three months from the time of enrollment until death or the last follow‐up. Data of all cases were collected retrospectively from the medical records and databases of each hospital. The definition of non‐smokers used was described in a previous study.[12](#tca12397-bib-0012){ref-type="ref"} Overall survival (OS) was defined as the period from receipt of chemotherapy to the time of death or last follow‐up. Progression‐free survival (PFS) was defined as the duration from the first treatment to the date of disease progression, death or last follow‐up. Therapeutic response was assessed after the first two or three cycles and determined by Response Evaluation Criteria in Solid Tumors version 1.1.[13](#tca12397-bib-0013){ref-type="ref"} The disease control rate (DCR) included complete response (CR), partial response (PR) and stable disease (SD). The objective response rate (ORR) consisted of complete response (CR) and partial response (PR).

Chemotherapy regimens {#tca12397-sec-0008}
---------------------

All participants received first‐line platinum‐based chemotherapy; the detailed chemotherapeutic regimens have previously been described.[12](#tca12397-bib-0012){ref-type="ref"}

Genotype analysis {#tca12397-sec-0009}
-----------------

Blood samples were collected from each participant and genomic DNA was extracted using the Human Whole Blood Genomic DNA Extraction Kit (Qiagen, Valencia, CA, USA). We analyzed samples for the *p73* G4C14‐to‐A4T14 polymorphism using the TaqMan Pre‐Designed SNP Genotyping Assay (Applied Biosystems, Foster City, CA, USA) following the manufacturer's instructions. The PCR primers used for amplifying *p73* G4C14‐A4T14 were as follows: 5′‐CAGGAGGACAGAGCACGAGTT‐3′ (forward) and 5′‐TGATGAGGGTGGCTAAGGCTA‐3′ (reverse). Approximately 15% of the samples were randomly selected for repeat genotyping by a different investigator, and the results were entirely concordant.

Statistical analysis {#tca12397-sec-0010}
--------------------

The distribution of selected variables and *p73* genotype frequencies between the discovery and replication sets were evaluated using the χ^2^ test. Hardy--Weinberg equilibrium was tested by a goodness‐of‐fit *χ* ^2^ test to compare the observed genotype frequencies. Survival curves were computed according to Kaplan--Meier curves. Univariate analysis was conducted using Cox's proportional hazard model to validate the significant variables related to survival. Multivariate analysis was then performed using variables with a univariate *P* \< 0.1. For chemotherapeutic response, unconditional multivariate logistic regression analysis was performed to estimate odds ratios (ORs), along with the corresponding 95% confidence intervals (CIs) for *p73* genotypes. All statistical analyses were accomplished using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA) and *P* values \<0.05 were considered statistically significant.

Results {#tca12397-sec-0011}
=======

Patient characteristics {#tca12397-sec-0012}
-----------------------

The demographic and clinical characteristics of the patients in the two study cohorts are presented in Table [1](#tca12397-tbl-0001){ref-type="table-wrap"}. In the discovery set, 456 (71.0%) patients were male and 382 (59.5%) were smokers. All patients had advanced inoperable NSCLC, with 40.8% in stage III and 59.2% in stage IV. The median OS and PFS of all patients were 19.27 (95% CI: 17.64--20.89) and 10.07 months (95% CI: 8.61--11.53), respectively. Patients with tumor node metastasis (TNM) stage IV and infrequent histological subtypes had significantly worse OS (*P* = 0.012 and *P* = 0.027, respectively) compared with patients with TNM stage III and adenocarcinoma (Fig [1](#tca12397-fig-0001){ref-type="fig"}a,b). In addition, Eastern Cooperative Oncology Group (ECOG) performance status was related to PFS and patients with higher scores showed a higher risk of recurrence or metastasis (*P* = 0.006; Fig [1](#tca12397-fig-0001){ref-type="fig"}c), whereas other clinical factors were not independent prognostic factors (Table [2](#tca12397-tbl-0002){ref-type="table-wrap"}).

###### 

Basic patient characteristics

  Variables         Discovery set (N, %)   Replication set (N, %)   *χ* ^2^   *P* [\*](#tca12397-note-0002){ref-type="fn"}
  ----------------- ---------------------- ------------------------ --------- ----------------------------------------------
  Age (years)                                                                 
  \<58              333 (51.9)             171 (51.8)               0.001     0.988
  ≥58               309 (48.1)             159 (48.2)                         
  Gender                                                                      
  Male              456 (71.0)             234 (70.9)               0.001     0.969
  Female            186 (29.0)             96 (29.1)                          
  Smoking history                                                             
  Non‐smokers       260 (40.5)             144 (43.6)               0.884     0.347
  Smokers           382 (59.5)             186 (56.4)                         
  ECOG PS                                                                     
  0--1              593 (92.4)             297 (90.0)               1.582     0.209
  2                 49 (7.6)               33 (10.0)                          
  Chemotherapy                                                                
  NP/NC             236 (36.8)             115 (34.8)               1.126     0.771
  GP/GC             174 (27.1)             95 (28.8)                          
  TP/TC             192 (29.9)             95 (28.8)                          
  DP/DC             40 (6.2)               25 (7.6)                           
  TNM stage                                                                   
  III               262 (40.8)             119 (36.1)               2.063     0.151
  IV                380 (59.2)             211 (63.9)                         
  Tumor histology                                                             
  Adeno             398 (62.0)             213 (64.5)               2.057     0.358
  SQC               147 (22.9)             66 (20.0)                          
  Others            97 (15.1)              51 (15.5)                          

*P*‐values derived from *χ* ^2^ test.

Adeno, adenocarcinoma; DP/DC, carboplatin or cisplatin plus docetaxel; ECOG PS, Eastern Cooperative Oncology Group performance status; GP/GC, carboplatin or cisplatin plus gemcitabine; NP/NC, carboplatin or cisplatin plus vinorelbine; SQC, squamous cell carcinoma; TNM, tumor node metastasis; TP/TC, carboplatin or cisplatin plus paclitaxel.

![Survival analysis. Kaplan--Meier curves of (**a**) tumor node metastasis (TNM) stage and overall survival (OS), (**b**) tumor histology and OS, (**c**) Eastern Cooperative Oncology Group performance status (ECOG PS) and progression‐free survival (PFS), (**d**) p73 G4C14‐to‐A4T14 and OS, and (**e**) p73 G4C14‐to‐A4T14 dominant model and OS in the discovery set. (**f**) p73 G4C14‐to‐A4T14 and OS in pooled populations.](TCA-8-63-g001){#tca12397-fig-0001}

###### 

Survival analysis in the discovery set

  Variables              N (%)        OS (95% CI) (m)[†](#tca12397-note-0004){ref-type="fn"}   *P* ~L‐R~   aHR (95% CI)[‡](#tca12397-note-0005){ref-type="fn"}   *P* [‡](#tca12397-note-0005){ref-type="fn"}
  ---------------------- ------------ -------------------------------------------------------- ----------- ----------------------------------------------------- ---------------------------------------------
  Age (years)                                                                                                                                                    
  \<58                   333 (51.9)   20.87 (18.73--23.00)                                     0.028       Reference                                             
  ≥58                    309 (48.1)   16.40 (14.04--18.76)                                                 1.17 (0.97--1.41)                                     0.095
  Gender                                                                                                                                                         
  Male                   456 (71.0)   18.67 (16.54--20.79)                                     0.049       Reference                                             
  Female                 186 (29.0)   20.87 (17.29--24.45)                                                 0.88 (0.65--1.18)                                     0.375
  Smoking history                                                                                                                                                
  Non‐smokers            260 (40.5)   20.23 (17.60--22.87)                                     0.084       Reference                                             
  Smokers                382 (59.5)   18.30 (15.93--20.67)                                                 1.03 (0.78--1.34)                                     0.858
  ECOG PS                                                                                                                                                        
  0--1                   593 (92.4)   19.37 (17.74--21.00)                                     0.121       Reference                                             
  2                      49 (7.6)     17.77 (8.76--26.77)                                                  1.24 (0.89--1.73)                                     0.206
  Chemotherapy                                                                                                                                                   
  NP/NC                  236 (36.8)   19.17 (16.30--22.03)                                     0.447       Reference                                             
  GP/GC                  174 (27.1)   19.27 (16.32--22.21)                                                 0.88 (0.70--1.11)                                     0.279
  TP/TC                  192 (29.9)   19.03 (15.99--22.08)                                                 1.03 (0.83--1.29)                                     0.779
  DP/DC                  40 (6.2)     22.00 (18.41--25.59)                                                 0.84 (0.58--1.23)                                     0.381
  TNM stage                                                                                                                                                      
  III                    262 (40.8)   20.67 (18.53--22.80)                                     0.029       Reference                                             
  IV                     380 (59.2)   17.80 (15.43--20.17)                                                 1.28 (1.06--1.54)                                     0.012
  Tumor histology                                                                                                                                                
  Adeno                  398 (62.0)   20.37 (18.31--22.43)                                     0.030       Reference                                             
  SQC                    147 (22.9)   15.27 (10.63--19.90)                                                 1.26 (0.99--1.60)                                     0.053
  Others                 97 (15.1)    15.30 (11.02--19.58)                                                 1.35 (1.03--1.76)                                     0.027
  *P73* G4C14‐to‐A4T14                                                                                                                                           
  GC/GC                  387 (60.3)   17.67 (15.71--19.62)                                     0.019       Reference                                             
  GC/AT                  212 (33.0)   21.37 (18.42--24.31)                                                 0.86 (0.71--1.05)                                     0.130
  AT/AT                  43 (6.7)     29.80 (19.38--40.22)                                                 0.65 (0.43--0.97)                                     0.035
  Dominant                                                                                                                                                       
  GC/AT + AT/AT          255 (39.7)   22.30 (19.08--25.52)                                     0.021       0.82 (0.68--0.99)                                     0.040
  GC/GC                  387 (60.3)   17.67 (15.71--19.62)                                                 Ref.                                                  
  Recessive                                                                                                                                                      
  AT/AT                  43 (6.7)     29.80 (19.38--40.22)                                     0.021       0.69 (0.46--1.02)                                     0.063
  GC/GC +GC/AT           599 (93.3)   19.03 (17.40--20.66)                                                 Reference                                             
  Additive               NA           NA                                                       NA          0.83 (0.72--0.97)                                     0.017

Survival derived from Kaplan--Meier analysis.

Hazard ratios (HRs), 95% confidence intervals (CIs) and their corresponding *P* values were calculated using univariate Cox proportional hazard models.

Adeno, adenocarcinoma; aHR, adjusted hazard ratio; ECOG PS, Eastern Cooperative Oncology Group performance status; GP/GC, carboplatin or cisplatin plus gemcitabine; m, months; NA, not available; NP/NC, carboplatin or cisplatin plus vinorelbine; OS, overall survival; *P* ~L‐R~, Log‐Rank *P*; SQC, squamous cell carcinoma; TNM, tumor node metastasis; TP/TC, carboplatin or cisplatin plus paclitaxel.

Among the 330 cases in the replication set, 234 (70.9%) were men and 186 (56.4%) were smokers, with 36.1% in stage III and 63.9% in stage IV disease. TNM stage and tumor histology also showed significant associations with OS, similar to the discovery set (Table [3](#tca12397-tbl-0003){ref-type="table-wrap"}). There were no statistically significant differences in variables between the discovery and replication sets (Table [1](#tca12397-tbl-0001){ref-type="table-wrap"}).

###### 

Distribution of p73 G4C14‐to‐A4T14 genotypes according to clinical factors

  Variables         Discovery set, n (%)   Replication set, n (%)                                                                           
  ----------------- ---------------------- ------------------------ ---------- ------- ------- ------------ ----------- ----------- ------- -------
  Age (years)                                                                                                                               
  \<58              202 (60.7)             112 (33.6)               19 (5.7)   1.112   0.574   102 (59.6)   54 (31.6)   15 (8.8)    0.670   0.715
  ≥58               185 (59.9)             100 (32.4)               24 (7.8)                   101 (63.5)   47 (29.6)   11 (6.9)            
  Gender                                                                                                                                    
  Male              280 (61.4)             148 (32.5)               28 (6.1)   1.112   0.545   145 (62.0)   73 (31.2)   16 (6.8)    1.225   0.542
  Female            107 (57.5)             64 (34.4)                15 (8.1)                   58 (60.4)    28 (29.2)   10 (10.4)           
  Smoking history                                                                                                                           
  Non‐smokers       150 (57.7)             90 (34.6)                20 (7.7)   1.467   0.480   84 (58.3)    48 (33.3)   12 (8.3)    1.108   0.575
  Smokers           237 (62.0)             122 (31.9)               23 (6.0)                   119 (64.0)   53 (28.5)   14 (7.5)            
  ECOG PS                                                                                                                                   
  0--1              355 (59.9)             196 (33.1)               42 (7.1)   1.942   0.379   181 (60.9)   92 (31.0)   24 (8.1)    0.445   0.800
  2                 32 (65.3)              16 (32.7)                1 (2.0)                    22 (66.7)    9 (27.3)    2 (6.1)             
  Chemotherapy                                                                                                                              
  NP/NC             137 (58.1)             83 (35.2)                16 (6.8)   6.962   0.324   74 (64.3)    31 (27.0)   10 (8.7)    9.509   0.147
  GP/GC             101 (58.0)             59 (33.9)                14 (8.0)                   54 (56.8)    33 (34.7)   8 (8.4)             
  TP/TC             127 (66.1)             57 (29.7)                8 (4.2)                    57 (60.0)    34 (35.8)   4 (4.2)             
  DP/DC             22 (55.0)              13 (32.5)                5 (12.5)                   18 (72.0)    3 (12.0)    4 (16.0)            
  TNM stage                                                                                                                                 
  III               161 (61.5)             78 (29.8)                23 (8.8)   4.379   0.112   74 (62.2)    33 (27.7)   12 (10.1)   1.665   0.435
  IV                226 (59.5)             134 (35.3)               20 (5.3)                   129 (61.1)   68 (32.2)   14 (6.6)            
  Tumor histology                                                                                                                           
  Adeno             236 (59.3)             133 (33.4)               29 (7.3)   1.307   0.860   130 (59.1)   69 (31.4)   21 (9.5)    3.682   0.451
  SQC               93 (63.3)              45 (30.6)                9 (6.1)                    42 (63.6)    21 (31.8)   3 (4.5)             
  Others            58 (59.8)              34 (35.1)                5 (5.2)                    31 (70.5)    11 (25.0)   2 (4.5)             

*P* values derived from *χ* ^2^ test.

Adeno, adenocarcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; GP/GC, carboplatin or cisplatin plus gemcitabine; m, months; NP/NC, carboplatin or cisplatin plus vinorelbine; SQC, squamous cell carcinoma; TNM, tumor node metastasis; TP/TC, carboplatin or cisplatin plus paclitaxel.

Survival analysis {#tca12397-sec-0013}
-----------------

### Discovery set {#tca12397-sec-0014}

All genotype frequencies for *p73* G4C14‐to‐A4T14 were in Hardy--Weinberg equilibrium (*P* \> 0.05). There was no significant difference in the genotype distributions of *p73* G4C14‐to‐A4T14 according to clinical factors (Table [3](#tca12397-tbl-0003){ref-type="table-wrap"}). We classified this polymorphism by models including genotypic, dominant, recessive, and additive. The results demonstrated that individuals with the AT/AT genotype have prolonged OS compared with GC/GC carriers (adjusted hazard ratio \[aHR\] = 0.65, *P* = 0.035), whereas heterozygotes showed no significance after adjusting for selected variables. In addition, patients carrying the AT allele (GC/AT or AT/AT) had significantly increased OS in the dominant model (for GC/AT + AT/AT genotype HR 0.82; *P* = 0.040). Kaplan--Meier curves also indicated these results (log‐rank test for the genotypic model *P* = 0.019, for the dominant model *P* = 0.021; Fig [1](#tca12397-fig-0001){ref-type="fig"}d,e; Table [2](#tca12397-tbl-0002){ref-type="table-wrap"}). However, none of genotypes showed a significant relationship with PFS (data not shown).

### Replication set and pooled analysis {#tca12397-sec-0015}

To validate the association of *p73* G4C14‐to‐A4T14 with OS, another independent replication set with 330 advanced NSCLC cases was performed. In this second group, the *p73* G4C14‐to‐A4T14 genotypes showed a similar trend of relationship with survival. We concluded that carriers of the AT/AT genotype were significantly associated with increased OS compared with the GC/GC genotype (aHR = 0.64, *P* = 0.040). The dominant (*P* = 0.014) and additive models (*P* = 0.015) of *p73* G4C14‐to‐A4T14 also showed a statistically significant association (Table [4](#tca12397-tbl-0004){ref-type="table-wrap"}).

###### 

Survival analysis in the replication set and pooled populations

  Variables              Replication set   Pooled populations                                                                                                          
  ---------------------- ----------------- ---------------------- ------- -------------------- ------- ------------ ---------------------- ------- ------------------- -------
  Age (years)                                                                                                                                                          
  \<58                   171 (51.8)        21.87 (17.35--26.38)   0.038   Ref.                         504 (51.9)   21.30 (19.25--23.35)   0.014   Reference           
  ≥58                    159 (48.2)        17.57 (14.67--20.47)           1.33 (1.02--1.741)   0.072   468 (48.1)   17.17 (15.30--19.03)           1.20 (1.03--1.40)   0.055
  Gender                                                                                                                                                               
  Male                   234 (70.9)        17.93 (15.31--20.55)   0.063   Ref.                         690 (71.0)   18.27 (16.64--19.89)   0.057   Reference           
  Female                 96 (29.1)         22.50 (16.47--28.53)           0.85 (0.60--1.18)    0.326   282 (29.0)   21.43 (17.95--24.92)           0.87 (0.69--1.10)   0.257
  Smoking history                                                                                                                                                      
  Non‐smokers            144 (43.6)        22.50 (17.87--27.13)   0.125   Ref.                         404 (41.6)   21.03 (18.69--23.38)   0.025   Reference           
  Smokers                186 (56.4)        17.57 (15.13--20.00)           1.18 (0.88--1.57)    0.269   568 (58.4)   17.93 (16.23--19.64)           1.05 (0.85--1.29)   0.412
  ECOG PS                                                                                                                                                              
  0--1                   297 (90.0)        19.40 (16.21--22.59)   0.482   Ref.                         890 (91.6)   19.40 (17.93--20.87)   0.081   Reference           
  2                      33 (10.0)         18.00 (7.13--28.87)            1.26 (0.80--1.89)    0.312   82 (8.4)     17.90 (11.14--24.66)           1.22 (0.94--1.59)   0.134
  Chemotherapy                                                                                                                                                         
  NP/NC                  115 (34.8)        17.87 (13.39--22.34)   0.687   Ref.                         351 (36.1)   18.63 (16.14--21.13)   0.399   Reference           
  GP/GC                  95 (28.8)         19.07 (13.67--24.46)           1.16 (0.84--1.60)    0.372   269 (27.7)   19.07 (16.37--21.76)           0.95 (0.79--1.14)   0.549
  TP/TC                  95 (28.8)         19.83 (15.48--24.19)           1.07 (0.78--1.48)    0.672   287 (29.5)   19.27 (17.25--21.29)           1.01 (0.85--1.22)   0.881
  DP/DC                  25 (7.6)          20.90 (11.11--30.69)           0.77 (0.42--1.40)    0.389   65 (6.7)     22.00 (18.01--25.99)           0.81 (0.59--1.12)   0.199
  TNM stage                                                                                                                                                            
  III                    119 (36.1)        21.43 (17.43--25.44)   0.018   Ref.                         381 (39.2)   21.03 (19.06--23.01)   0.012   Reference           
  IV                     211 (63.9)        17.87 (14.72--21.02)           1.39 (1.06--1.834)   0.022   591 (60.8)   17.87 (16.04--19.70)           1.30 (1.12--1.52)   0.006
  Tumor histology                                                                                                                                                      
  Adeno                  213 (64.5)        20.67 (17.13--24.20)   0.081   Ref.                         618 (63.6)   20.57 (18.71--22.43)   0.007   Reference           
  SQC                    66 (20.0)         17.57 (12.86--22.27)           1.27 (0.89--1.68)    0.192   213 (21.9)   16.63 (13.12--20.15)           1.16 (0.96--1.42)   0.140
  Others                 51 (15.5)         18.00 (14.48--21.53)           1.58 (1.08--2.32)    0.019   141 (14.5)   16.40 (13.11--19.69)           1.37 (1.10--1.70)   0.010
  *P73* G4C14‐to‐A4T14                                                                                                                                                 
  GC/GC                  203 (61.5)        16.37 (14.23--18.50)   0.035   Ref.                         590 (60.7)   17.00 (15.36--18.64)   0.001   Reference           
  GC/AT                  101 (30.6)        24.03 (18.76--29.31)           0.74 (0.55--0.99)    0.083   313 (32.2)   21.87 (19.08--24.66)           0.83 (0.71--0.97)   0.022
  AT/AT                  26 (7.9)          27.43 (15.97--38.90)           0.64 (0.38--1.06)    0.040   69 (7.1)     29.80 (22.32--37.28)           0.65 (0.47--0.89)   0.007
  Dominant                                                                                                                                                             
  GC/AT + AT/AT          127 (38.5)        25.13 (20.66--29.61)   0.015   0.72 (0.55--0.94)    0.014   382 (39.3)   22.63 (20.04--25.23)   0.001   0.80 (0.68--0.93)   0.003
  GC/GC                  203 (61.5)        16.37 (14.23--18.50)           Ref.                         590 (60.7)   17.00 (15.36--18.64)           Reference           
  Recessive                                                                                                                                                            
  AT/AT                  26 (7.9)          32.83 (22.11--43.56)   0.083   0.70 (0.42--1.16)    0.165   69 (7.1)     29.80 (22.32--37.28)   0.014   0.69 (0.51--0.95)   0.032
  GC/GC + GC/AT          304 (92.1)        18.93 (16.26--21.61)           Ref.                         903 (92.9)   18.93 (17.53--20.34)           Reference           
  Additive               NA                NA                     NA      0.77 (0.63--0.95)    0.015   NA           NA                     NA      0.82 (0.72--0.92)   0.001

Survival derived from Kaplan--Meier analysis.

Hazard ratios (HRs), 95% confidence intervals (CIs) and their corresponding *P* values were calculated using univariate Cox proportional hazard models.

Adeno, adenocarcinoma; aHR, adjusted hazard ratio; ECOG PS, Eastern Cooperative Oncology Group performance status; GP/GC, carboplatin or cisplatin plus gemcitabine; m, months; NP/NC, carboplatin or cisplatin plus vinorelbine; OS, overall survival; *P* ~L~ ~‐~ ~R~, Log‐Rank *P*; SQC, squamous cell carcinoma; TNM, tumor node metastasis; TP/TC, carboplatin or cisplatin plus paclitaxel.

Further pooled analysis of the two cohorts verified the previously observed association of the *p73* G4C14‐to‐A4T14 polymorphism with OS. Kaplan--Meier curves and log‐rank tests showed that both the AT/AT variant homozygotes and the GC/AT heterozygotes were significantly correlated with prolonged OS compared with the GC/GC homozygotes in the 972 NSCLC patients (*P* = 0.001; Fig [1](#tca12397-fig-0001){ref-type="fig"}f). Univariate Cox regression analysis also confirmed this association (for GC/AT + AT/AT genotype HR 0.80; *P* = 0.003; for AT/AT genotype HR 0.69; *P* = 0.032; for additive model HR 0.82, *P* = 0.001) after adjusting for clinical variables (Table [3](#tca12397-tbl-0003){ref-type="table-wrap"}). Furthermore, we included age (≥58 vs. \<58), TNM stage (TNM IV vs. TNM III), tumor histology (adenocarcinoma, squamous, or others), and the *p73* G4C14‐to‐A4T14 dominant and recessive models in multivariate Cox regression analysis. The results suggested that TNM stage (*P* = 0.004), tumor histology (*P* = 0.022), and dominant model (*P* = 0.017) were independent predictive factors for OS (Table [5](#tca12397-tbl-0005){ref-type="table-wrap"}).

###### 

Multivariate Cox regression analysis of prognostic factors for overall survival in pooled populations

  Variables                HR (95% CI)         *P*
  ------------------------ ------------------- -------
  Age (≥58 vs. \<58)       1.25 (0.96--1.55)   0.062
  TNM stage (IV vs. III)   1.30 (1.11--1.51)   0.004
  Tumor histology                              0.022
  Adeno                    Ref.                
  SQC                      1.22 (1.01--1.47)   0.041
  Others                   1.38 (1.12--1.71)   0.013
  *P73* G4C14‐to‐A4T14                         
  Dominant                 0.82 (0.70--0.97)   0.017
  Recessive                0.75 (0.54--1.04)   0.086

All of the variables yielding *P* values \< 0.1 in the univariate analysis were used for multivariate Cox regression analysis. Adeno adenocarcinoma; CI, confidence interval; HR, hazard ratio; SQC squamous cell carcinoma; TNM, tumor node metastasis.

Stratification analysis {#tca12397-sec-0016}
-----------------------

To better understand the potential impact of the *p73* G4C14‐to‐A4T14 polymorphism on survival in NSCLC patients, we performed subgroup analysis stratified by confounding variables in the pooled populations. Because the AT/AT genotype was relatively infrequent, we combined it with the GC/AT genotype for further examination. As shown in Table [6](#tca12397-tbl-0006){ref-type="table-wrap"}, the favorable effect of the *p73* combined genotypes (GC/AT + AT/AT) was more evident in patients who were older (≥58 years) at diagnosis (*P* = 0.001), male (*P* = 0.007), smokers (*P* = 0.006), had a low ECOG performance status (0--1; *P* = 0.001), in TNM stage IV (*P* = 0.008), and with adenocarcinoma (*P* = 0.002). However, we did not find any interaction between the *p73* variant genotypes and chemotherapeutic regimens for overall survival in NSCLC patients.

###### 

Association between p73 genotypes and OS stratified by selected variables

  Variables         GC/GC        GC/GC + AT/AT          aHR (95% CI)[†](#tca12397-note-0013){ref-type="fn"}   *P* [†](#tca12397-note-0013){ref-type="fn"}                              
  ----------------- ------------ ---------------------- ----------------------------------------------------- --------------------------------------------- ------ ------------------- -------
  Age (years)                                                                                                                                                                          
  \<58              305 (60.5)   19.93 (17.61--22.25)   199 (39.5)                                            23.33 (20.07--26.60)                          1.00   0.90 (0.72--1.11)   0.305
  ≥58               285 (60.9)   15.07 (13.31--16.83)   183 (39.1)                                            22.40 (18.09--26.71)                          1.00   0.70 (0.56--0.86)   0.001
  Gender                                                                                                                                                                               
  Male              422 (61.2)   15.97 (14.15--17.78)   268 (38.8)                                            21.73 (18.88--24.59)                          1.00   0.78 (0.66--0.94)   0.007
  Female            168 (59.6)   19.27 (16.17--22.37)   114 (40.4)                                            22.80 (19.38--26.22)                          1.00   0.83 (0.55--1.18)   0.125
  Smoking history                                                                                                                                                                      
  Non‐smokers       236 (58.4)   19.07 (16.33--21.80)   168 (41.6)                                            23.57 (20.11--27.03)                          1.00   0.81 (0.64--1.02)   0.078
  Smokers           354 (62.3)   15.90 (13.92--17.88)   214 (37.7)                                            22.30 (17.90--26.70)                          1.00   0.76 (0.62--0.93)   0.006
  ECOG PS                                                                                                                                                                              
  0--1              535 (60.1)   17.17 (15.44--18.90)   355 (39.9)                                            23.87 (21.06--26.68)                          1.00   0.77 (0.66--0.90)   0.001
  2                 55 (67.1)    17.77 (9.42--26.12)    27 (32.9)                                             19.43 (12.59--26.28)                          1.00   0.93 (0.60--1.59)   0.890
  Chemotherapy                                                                                                                                                                         
  NP/NC             208 (59.3)   16.27 (13.06--19.48)   143 (40.7)                                            20.40 (15.01--25.79)                          1.00   0.89 (0.69--1.15)   0.371
  GP/GC             157 (58.4)   17.47 (14.98--19.95)   112 (41.6)                                            25.37 (20.18--30.56)                          1.00   0.75 (0.56--1.01)   0.055
  TP/TC             185 (64.5)   17.97 (14.41--21.52)   102 (35.5)                                            22.27 (17.82--26.71)                          1.00   0.79 (0.60--1.04)   0.091
  DP/DC             40 (61.5)    18.40 (12.83--23.97)   25 (38.5)                                             23.33 (11.22--35.45)                          1.00   0.71 (0.37--1.38)   0.313
  TNM stage                                                                                                                                                                            
  III               237 (62.2)   19.10 (16.81--21.40)   144 (37.8)                                            24.10 (20.16--28.04)                          1.00   0.79 (0.62--1.01)   0.059
  IV                353 (59.7)   15.20 (13.18--17.22)   238 (40.3)                                            21.73 (17.69--25.78)                          1.00   0.77 (0.63--0.93)   0.008
  Tumor histology                                                                                                                                                                      
  Adeno             370 (59.9)   18.10 (16.02--20.19)   248 (40.1)                                            25.80 (21.81--29.79)                          1.00   0.74 (0.62--0.90)   0.002
  SQC               133 (62.4)   14.57 (11.04--18.09)   80 (37.6)                                             21.87 (14.93--28.81)                          1.00   0.76 (0.55--1.06)   0.108
  Others            87 (61.7)    16.40 (12.90--19.90)   54 (38.3)                                             18.30 (11.54--25.07)                          1.00   0.95 (0.71--1.26)   0.797

Hazard ratios (HRs), 95% confidence intervals (CIs) and their corresponding *P* values were calculated using multivariate Cox proportional hazard models, adjusted for all clinical factors.

Survival derived from Kaplan--Meier analysis.

Adeno, adenocarcinoma; aHR, adjusted hazard ratio; ECOG PS, Eastern Cooperative Oncology Group performance status; GP/GC, carboplatin or cisplatin plus gemcitabine; m, months; NP/NC, carboplatin or cisplatin plus vinorelbine; OS, overall survival; *P* ~L~ ~‐~ ~R~, Log‐Rank *P*; SQC, squamous cell carcinoma; TNM, tumor node metastasis; TP/TC, carboplatin or cisplatin plus paclitaxel.

P73 G4C14‐to‐A4T14 and chemotherapy efficacy {#tca12397-sec-0017}
--------------------------------------------

The chemotherapeutic response of patients was assessed in the pooled populations. Disease control was noted in 761 (78.3%) patients, and objective response was achieved in 163 (16.8%). A marginally significant association with ORR other DCR for *p73* G4C14‐to‐A4T14 was manifested by multivariate logistic regression analysis in the 972 NSCLC cases (for GC/AT + AT/AT genotype OR, 0.69; *P* = 0.047; Table [7](#tca12397-tbl-0007){ref-type="table-wrap"}).

###### 

Correlations of p73 genotypes with chemotherapy efficacy in pooled populations

  Genotypes      ORR (CR + PR)    DCR (CR + PR + SD)                                                                                       
  -------------- --------------- -------------------- ------- ------------------- ------- ------------ ------- ------- ------------------- -------
  GC/GC          87 (14.8)              4.272          0.039       Reference              468 (79.3)    1.122   0.294       Reference      
  GC/AT+ AT/AT   76 (19.9)                                     0.69 (0.41--0.93)   0.047  293 (76.7)                    0.92 (0.64--1.45)   0.374

*P* values derived from *χ* ^2^ test.

Odds ratios (ORs), 95% confidence intervals (CIs) and their corresponding *P* values were calculated using multivariate logistic regression analysis, adjusted for all clinical factors.

CR, complete response; DCR, disease control rate; ORR, objective response rate; PR, partial response; SD, stable disease.

Discussion {#tca12397-sec-0018}
==========

The principal finding of the present study is that the *p73* G4C14‐to‐A4T14 polymorphism may be related to survival outcomes in advanced NSCLC patients who receive platinum‐based chemotherapy. Given the role of *p73* as an important regulator of cell cycle and DNA repair, it is biologically plausible that this well known SNP may potentially modulate the chemotherapy efficacy of DNA‐damaging anti‐cancer drugs, including platinum agents.

DNA damage in the G1 phase induced by platinum agents leads to the activation of cell cycle checkpoints, such as the *p53* tumor suppressor, resulting in either G1 arrest or programmed cell death.[14](#tca12397-bib-0014){ref-type="ref"} Like *p53*, *p73* has also been shown to respond to DNA damage, causing induction of cell cycle arrest or apoptosis.[15](#tca12397-bib-0015){ref-type="ref"} Because genetic polymorphisms in DNA repair genes, including the *p53* Arg72Pro polymorphism, they potentially influence the activity of chemotherapeutic agents. We hypothesized that *p73* genetic polymorphisms could also contribute to the individual variability of drug response. Two landmark articles showed that *p73* is an important determinant of chemosensitivity in humans, and its function is highly integrated with that of *p53*.[16](#tca12397-bib-0016){ref-type="ref"} [17](#tca12397-bib-0017){ref-type="ref"} Several other articles have confirmed the importance of *p73* expression in the prediction of tumor chemosensitivity and cancer prognosis by studying different tumor types.[18](#tca12397-bib-0018){ref-type="ref"}, [19](#tca12397-bib-0019){ref-type="ref"}, [20](#tca12397-bib-0020){ref-type="ref"}, [21](#tca12397-bib-0021){ref-type="ref"} The regulatory mechanisms are primarily linked to posttranslational modifications and protein‐protein interactions involving both signaling molecules and transcription factors. Indeed, mechanical behavior may be complex and variable, as it is dependent on the specific drugs and tissues involved. Thus, research on the genetic variants of the *p73* gene relevant to DNA damage may contribute to fully understanding or predicting the effect of chemotherapy.

Recently, an increasing number of studies have suggested that this validated polymorphism of *p73* not only influences the development, but also has an impact on the progression and prognosis of various cancers. For example, Carastro *et al.* demonstrated that *p73* G4C14‐to‐A4T14 has a significant inverse relationship with aggressiveness and a marginal association with overall death in prostate cancer.[22](#tca12397-bib-0022){ref-type="ref"} Pfeifer *et al.* reported that colorectal cancer patients with the AT allele had a better prognosis than those with the GC/GC genotype.[23](#tca12397-bib-0023){ref-type="ref"} Lee *et al.* concluded that the *p73* GC/AT genotype is associated with increased risk and survival of colorectal cancer in a Korean population.[24](#tca12397-bib-0024){ref-type="ref"} Liu *et al*. demonstrated the combined effect of genetic polymorphisms in the *p53*, *p73*, and *MDM2* genes on NSCLC survival.[25](#tca12397-bib-0025){ref-type="ref"} However, the fairly small sample size and marginal significance mean that these results should be considered with caution. Liu *et al*.'s study was the only one to investigate the association between the *p73*G4C14‐to‐A4T14 polymorphism and the response of lung adenocarcinoma cell lines to chemotherapy.[26](#tca12397-bib-0026){ref-type="ref"} Nevertheless, the authors also considered that the negative results should be validated further in a prospective study with a larger group of patients. In our opinion, the in vitro assay may not be adequate to simulate the function of chemotherapy drugs in tumor patients. In our study, we found a significant correlation between the *p73* G4C14‐to‐A4T14 polymorphism and survival outcomes in a Chinese population of advanced NSCLC patients treated with platinum‐based chemotherapy. Patients with AT/AT and GC/AT genotypes had a more favorable response and better overall survival than those with the GC/GC genotype, which is consistent with previous published results. This may be explained by variation from the GC to AT allele, leading to the formation of a stem‐loop structure, thus modulating the translation efficiency of *p73* in tumors.

The present study has several strengths. We used two relatively large cohorts from four independent oncological departments for the discovery and validation of the association between the *p73* G4C14‐to‐A4T14 polymorphism and clinical outcomes in advanced NSCLC patients. To ensure relatively homogeneous treatment, only those subjects who did not receive surgery and radiation therapy were enrolled. In addition, we also evaluated this polymorphism classified by models including genotypic, dominant, recessive, and additive. However, we acknowledge that there are several limitations. First is the retrospective nature of the study. Second, further investigations of the mechanism behind this polymorphism and potential functions need to be conducted. Third, because the *p73* gene has two alternative splicing transcripts, including TAp73 and ΔNp73, understanding the distribution of different isoforms may help to illuminate the role of the *p73* gene in different types of cancers.

In conclusion, our findings indicated that the *p73* G4C14‐to‐A4T14 polymorphism may be related to survival outcomes in advanced NSCLC patients following platinum‐based chemotherapy. However, further studies are required to investigate the underlying mechanism by which this common *p73* SNP affects outcomes in advanced NSCLC patients.
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